HSCI and Natsimbio Holding, owned by Rostec, will create a combined vaccine to prevent coronavirus and influenza. The composition of the drug will include components against four strains of influenza viruses produced by Rostec and HSCI's patented vaccine platform. Clinical trials will begin in the 2nd half of 2022.